BRPI0917411A2 - composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. - Google Patents

composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Info

Publication number
BRPI0917411A2
BRPI0917411A2 BRPI0917411A BRPI0917411A BRPI0917411A2 BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2 BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2
Authority
BR
Brazil
Prior art keywords
cell
subject
rassf1a
cells
dansyl
Prior art date
Application number
BRPI0917411A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathryn D Sheikh
Mikell Paige
Milton L Brown
Partha Banerjee
Shankar Jagadeesh
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of BRPI0917411A2 publication Critical patent/BRPI0917411A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0917411A 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. BRPI0917411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (1)

Publication Number Publication Date
BRPI0917411A2 true BRPI0917411A2 (pt) 2015-12-01

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917411A BRPI0917411A2 (pt) 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Country Status (9)

Country Link
US (1) US10457639B2 (https=)
EP (2) EP2323982B1 (https=)
JP (2) JP2012500197A (https=)
CN (1) CN102186820B (https=)
AT (1) ATE547403T1 (https=)
AU (1) AU2009282451B2 (https=)
BR (1) BRPI0917411A2 (https=)
CA (1) CA2734225A1 (https=)
WO (1) WO2010019271A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
ES2641642T3 (es) 2010-03-08 2017-11-10 Monsanto Technology Llc Moléculas de polinucleótido para regulación génica en plantas
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
EP3382027A3 (en) 2011-09-13 2018-10-31 Monsanto Technology LLC Methods and compositions for weed control
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
MX348495B (es) 2011-09-13 2017-06-14 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
MX361938B (es) 2011-09-13 2018-12-19 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
MX360866B (es) 2012-05-24 2018-11-09 A B Seeds Ltd Composiciones y métodos para silenciar la expresión genética.
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UY35252A (es) 2013-01-01 2014-07-31 Seeds Ltd Ab MÉTODOS PARA INTRODUCIR dsRNA EN SEMILLAS DE PLANTAS PARA MODULAR LA EXPRESIÓN GENÉTICA
BR112015023051A2 (pt) 2013-03-13 2017-11-14 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
EP3030663B1 (en) 2013-07-19 2019-09-04 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
AU2014341879B2 (en) 2013-11-04 2020-07-23 Greenlight Biosciences, Inc. Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
CN106795515B (zh) 2014-06-23 2021-06-08 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
CN106604993A (zh) 2014-07-29 2017-04-26 孟山都技术公司 用于控制昆虫害虫的组合物和方法
CN108064288B (zh) 2015-01-22 2021-11-26 孟山都技术公司 用于控制叶甲属的组合物和方法
EP3302053B1 (en) 2015-06-02 2021-03-17 Monsanto Technology LLC Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
WO2017023916A1 (en) 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
JP7236382B2 (ja) * 2017-06-12 2023-03-09 昇平 宮田 抗癌剤及びその使用
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
US5834462A (en) * 1993-07-26 1998-11-10 Eisai Co., Ltd. Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) * 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
JP3887769B2 (ja) 1997-12-22 2007-02-28 バイエル コーポレイション 対称および非対称ジフェニル尿素を用いるp38キナーゼの阻害
WO2000063171A1 (en) * 1999-04-20 2000-10-26 Meiji Seika Kaisha, Ltd. Tricyclic compounds
KR20020069215A (ko) 1999-12-16 2002-08-29 아사히 가세이 가부시키가이샤 신규한 치환기를 갖는 3환성 화합물
AU2001252575A1 (en) 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
KR20090090406A (ko) * 2000-12-18 2009-08-25 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 염증성 사이토카인 생산 유리 억제제
WO2002060867A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074306A1 (ja) 2001-03-19 2004-07-08 旭化成ファーマ株式会社 脂肪肝治療薬
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20100063126A1 (en) 2004-06-29 2010-03-11 Jadolabs Gmbh Carbazole-Derived Pharmaceutical Compositions
WO2006018405A1 (en) 2004-08-18 2006-02-23 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
DE112006002340T5 (de) 2005-09-01 2008-07-17 Council Of Scientific And Industrial Research Arzneimittel, verwendbar zur Behandlung von Prostatakrebs
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
NZ567266A (en) 2005-10-13 2010-09-30 Orchid Res Lab Ltd Carbazole derivatives as pSTAT3/IL-6 inhibitors (carvedilol)
US20100130579A1 (en) * 2006-10-23 2010-05-27 Georgetown University Cancer therapy
IL186935A0 (en) * 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
AU2008345036A1 (en) * 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of MINT loci and tumor-related genes as a marker for melanoma and breast cancer
WO2009118292A1 (en) 2008-03-24 2009-10-01 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
WO2010019271A1 (en) 2010-02-18
EP2323982B1 (en) 2012-02-29
JP2012500197A (ja) 2012-01-05
ATE547403T1 (de) 2012-03-15
CN102186820A (zh) 2011-09-14
JP2014148545A (ja) 2014-08-21
EP2484666A1 (en) 2012-08-08
HK1158206A1 (en) 2012-07-13
AU2009282451A1 (en) 2010-02-18
CA2734225A1 (en) 2010-02-18
US20110152339A1 (en) 2011-06-23
EP2323982A1 (en) 2011-05-25
US10457639B2 (en) 2019-10-29
WO2010019271A8 (en) 2011-03-31
AU2009282451B2 (en) 2014-02-13
CN102186820B (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
BRPI0917411A2 (pt) composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.
Durinck et al. Epigenetic regulation of neuroblastoma development
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
ATE513832T1 (de) 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
EA201290389A1 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2010003368A (es) Derivados de imidazol.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
ECSP088598A (es) Derivados de piridazinona
ZA200701137B (en) Triazolophthalazines
BRPI0518198B8 (pt) método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
BRPI0511138A (pt) derivados de pirimidina para o tratamento de desenvolvimento celular anormal
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
MX2021009987A (es) Metodos para el etiquetado de celulas eucariotas de un organismo multicelular utilizando compuestos monosacaridos modificados.
BR0303012A (pt) Avaliação de câncer colorretal
Qi et al. Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma
UA96745C2 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
LU et al. Expression and clinical significance of Mel-18 mRNA in gastric carcinoma
RUAN Expression of fatty acid synthase in lung cancer and its clinical significance

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]